loading page

Interaction between baseline HBV loads and the prognosis of patients with HCC who receive anti-PD-1 in combination with an antiangiogenic therapy and are simultaneously given TAF prophylaxis
  • +3
  • Xiaoyun Hu,
  • Rong Li,
  • Qi Li,
  • Mengya Zang,
  • Guosheng Yuan,
  • Jinzhang Chen
Xiaoyun Hu
Southern Medical University Nanfang Hospital
Author Profile
Rong Li
Southern Medical University Nanfang Hospital
Author Profile
Qi Li
Southern Medical University Nanfang Hospital
Author Profile
Mengya Zang
Southern Medical University Nanfang Hospital
Author Profile
Guosheng Yuan
Southern Medical University Nanfang Hospital
Author Profile
Jinzhang Chen
Southern Medical University Nanfang Hospital

Corresponding Author:[email protected]

Author Profile

Abstract

Aims: A high baseline hepatitis B virus (HBV) load has always been listed as an exclusion criterion for programmed cell death-1 (PD-1) inhibitor-associated therapy in clinical trials, as the interaction between HBV load and anti-PD-1/PD-L1 therapy remains controversial. Methods: We performed a retrospective cohort study of unresectable HCC patients who were seropositive for HBsAg and accepted tenofovir alafenamide fumarate (TAF) therapy before anti-PD-1 in combination with an antiangiogenic treatment. Patients were divided into a low HBV DNA group (≤ 2000 IU/ml) and a high HBV DNA group (> 2000 IU/ml) according to the baseline HBV DNA levels. Tumour response and progression-free survival (PFS) were compared, and univariate and multivariate Cox analyses were performed to identify potential risk factors for PFS. The incidences of HBV reactivation and HBV-associated hepatitis were also recorded. Results: Seventy eligible patients were included: 48 in the low group and 22 in the high group. The objective response rates (ORRs), disease control rates (DCRs), and PFS did not differ significantly between the two groups (P = 0.761, 0.552, and 0.784, respectively). The results of Cox analyses revealed that the baseline HBV load did not affect PFS. Additionally, HBV reactivation occurred in only 2 patients (2.9%), and no patient experienced HBV-related hepatic impairment when given a continuous TAF treatment. Conclusions: Baseline HBV loads do not affect the prognosis of HCC patients receiving anti-PD-1 in combination with an antiangiogenic therapy, while PD-1 inhibitors do not aggravate HBV reactivation and hepatic impairment in patients simultaneously subjected to TAF prophylaxis.